Abstract
In 2018, the Australian Government allocated $500 million for a 10‐year Australian Genomics Health Futures Mission. The first project announced was ‘Mackenzie’s Mission’ – a $20 million trial of pre‐conception screening for rare and debilitating genetic birth disorders. The increasing focus on genomic medicine in Australia, which is also occurring in other countries, raises important questions about what the investment means for public health, and what trade‐offs may occur as a result. As Joyner et al. noted: “After several decades of substantial investment [in genomics and other big ideas], the fundamental question is whether these big ideas have improved quality of life and life expectancy, by how much, for how many, and for whom.” While Joyner et al. were speaking of the United States context, the same questions apply to Australia...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Australian and New Zealand Journal of Public Health
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
